Patient characteristics
| Total (n=136) | CTRCD (n=23) | Non-CTRCD (n=113) | P value* | |
| Age, years | 51 (37–61)† | 52 (36–61) | 51 (37–61) | 0.965 |
| Male | 75 (55) | 9 (39) | 66 (58) | 0.110 |
| CCr, mL/min | 100 (81–123) | 89 (63–101) | 103 (82–127) | 0.026 |
| Cardiac risk factors | ||||
| Diabetes | 16 (12) | 4 (17) | 12 (11) | 0.475 |
| Hypertension | 18 (13) | 4 (17) | 14 (12) | 0.507 |
| Dyslipidaemia | 11 (8) | 1 (4) | 10 (9) | 0.690 |
| Current smoker | 34 (24) | 4 (17) | 3 (26) | 0.437 |
| Cardiac risk factors≥2 | 34 (25) | 4 (17) | 30 (27) | 0.283 |
| DXR before HSCT | ||||
| Cumulative DXR dose, mg/m2 | 231 (175–359) | 296 (180–400) | 208 (150–344) | 0.087 |
| Cumulative DXR dose ≥250 mg/m2 | 60 (44) | 13 (57) | 47 (42) | 0.250 |
| Baseline LVEF, % | 68 (63–73) | 66 (64–70) | 69 (63–74) | 0.158 |
| RAS inhibitors or beta-blockers | 2 (1) | 1 (4) | 1 (1) | 0.311 |
| Cardiac biomarker‡ | ||||
| Brain natriuretic peptide, pg/ml | 41 (12–73) | 23 (11–157) | 41 (13–67) | 0.908 |
| Troponin T, 10-2 ng/mL | 1.0 (0.4–2.5) | 2.3 (0.5–5.3) | 1.0 (0.4–1.5) | 0.428 |
| Primary disease | ||||
| Leukaemia | 98 (72) | 16 (70) | 82 (73) | 0.801 |
| Acute myeloid leukaemia | 60 (44) | 13 (57) | 47 (42) | 0.250 |
| Acute lymphoblastic leukaemia | 21 (15) | 3 (13) | 18 (16) | 1.000 |
| Chronic myeloid leukaemia | 2 (1) | 0 (0) | 2 (2) | 1.000 |
| Other type leukaemia | 15 (11) | 0 (0) | 15 (13) | 0.074 |
| Lymphoma | 35 (26) | 6 (26) | 29 (26) | 1.000 |
| Plasma cell neoplasm | 3 (2) | 1 (4) | 2 (2) | 0.429 |
| History of prior HSCT | 34 (27) | 9 (39) | 28 (25) | 0.199 |
| Non-CR status at HSCT | 89 (65) | 18 (78) | 71 (63) | 0.229 |
| Source of HSCT | ||||
| Bone marrow | 58 (43) | 8 (35) | 50 (44) | 0.491 |
| Cord blood | 34 (25) | 7 (30) | 27 (24) | 0.598 |
| PBSC | 44 (32) | 8 (35) | 36 (32) | 0.801 |
| Haploidentical donor | 13 (10) | 3 (13) | 10 (9) | 0.461 |
| HLA mismatch ≥one locus | 81 (60) | 17 (74) | 64 (57) | 0.163 |
| Conditioning regimen with MAC | 51 (38) | 5 (22) | 46 (41) | 0.102 |
| HCT-CI ≥3 points | 15 (11) | 5 (22) | 10 (9) | 0.135 |
| GVHD prophylaxis including tacrolimus | 107 (79) | 16 (70) | 91 (81) | 0.268 |
| Acute GVHD ≥Grade III | 24 (18) | 8 (35) | 16 (14) | 0.032 |
*CTRCD versus non-CTRCD.
†Values are presented as n (%) or median (25th to 75th percentile).
‡Values before HSCT, 60 in brain natriuretic peptide and 113 in troponin T were missing values.
CCr, creatinine clearance; CR, complete remission; CTRCD, cancer therapy-related cardiac dysfunction; DXR, doxorubicin; GVHD, graft-versus-host disease; HCT-CI, haematopoietic cell transplantation-specific comorbidity index; HLA, human leukocyteleucocyte antigen; HSCT, haematopoietic stem cell transplantation; LVEF, left ventricular ejection fraction; MAC, myeloablative conditioning; PBSC, peripheral blood stem cell; RAS, renin-angiotensin system.